Helicobacter pylori specific nested PCR assay for the detection of 23S rRNA mutation associated with clarithromycin resistance

S Maeda, H Yoshida, K Ogura, F Kanai, Y Shiratori, M Omata

Abstract

Background—Clarithromycin is one of the most important antibiotics for Helicobacter pylori eradication. However, 5–10% of strains are reported to be resistant. It has been shown that one point mutation in the 23S rRNA gene is associated with resistance to clarithromycin.

Aims—To establish a polymerase chain reaction (PCR) system which amplifies a segment of the 23S rRNA gene containing the mutation points with primers specific for H pylori, so that H pylori infection and the mutation associated with clarithromycin resistance can be examined simultaneously.

Methods—To detect H pylori infection and the mutation simultaneously, primers specific for the H pylori 23S rRNA gene were designed based on sequence conservation among H pylori strains and sequence specificity as compared with other bacteria. DNA from 57 cultured strains and from 39 gastric juice samples was amplified in the seminested 23S rRNA PCR. Clinical applicability was evaluated in 85 patients.

Results—DNA samples from 57 cultured strains were all amplified. The novel assay and the urease A PCR agreed in 37/39 gastric juice samples with no false positives. The assay did not amplify the DNA of bacteria other than H pylori. Eight of 85 samples had the mutation before treatment. In clarithromycin based treatment, eradication was achieved in 2/5 (40%) with the mutation and 29/34 (85%) without the mutation.

Conclusion—The assay using gastric juice is quick (within 12 hours) and non-invasive (endoscopy not required), enabling rapid initiation of appropriate antibiotic treatment.

Keywords: Helicobacter pylori; eradication; clarithromycin; resistance; point mutation

Helicobacter pylori is a Gram negative bacterium which resides in the human stomach. The organism plays an important role in the pathogenesis of not only persistent gastritis but also peptic ulcers and gastric cancer. Eradication of H pylori may reduce the risk of peptic ulcer and gastric carcinoma. The National Institutes of Health Consensus Development Conference has recommended the addition of antimicrobial agents to antisecretory drugs (proton pump inhibitors or H2 blockers) to treat patients with H pylori infection associated with peptic ulcer disease. These antibiotics include amoxicillin, clarithromycin, and metronidazole and the eradication rates achieved by one week of triple therapy were above 90%. All H pylori strains were shown to be susceptible to amoxicillin, but 5–10% of strains are resistant to clarithromycin and 10–50% to metronidazole. In the analysis of clarithromycin based treatment failure, et al reported that eradication was achieved in 3/10 (30%) clarithromycin resistant strains compared with 77/93 (83%) clarithromycin susceptible strains. Debets-Ossenkopp et al reported that 11/15 cases of unsuccessful eradication were due to clarithromycin resistance. These observations suggest the importance of evaluating drug resistance before and after treatment.

Recently, Versalovic et al showed that an adenine (A) to guanine (G) mutation at 2143 or 2144 in domain V of the 23S rRNA gene of H pylori is associated with resistance to clarithromycin. They also established a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay using primers conserved among most bacteria. However, the assessment of clarithromycin resistance with this assay requires culture of the bacterium beforehand, and takes about five to six days. The 23S rRNA gene is well conserved among various bacterial species and contamination will interfere with the assay.

The purpose of the current study was to establish a PCR system which amplifies a segment of the 23S rRNA gene containing the mutation points with primers specific for H pylori, so that H pylori infection and the mutation associated with clarithromycin resistance can be examined simultaneously.

Materials and methods

BACTERIAL STRAINS AND GROWTH MEDIA

Fifty seven H pylori strains were isolated from gastric biopsy specimens from pretreatment Japanese patients and the biopsy specimens were cultured on Columbia agar with 5% (vol/vol) horse blood and Dent antibiotic supplement (Oxoid, Basingstoke, UK) at 37°C for five days under microaerobic conditions.
The organisms were identified as *H. pylori* by Gram stain morphology, colony morphology, and positive urease, catalase, and oxidase activities. The isolates were kept at −80°C in Brucella broth with 5% (vol/vol) fetal bovine serum (FBS) containing 16% (vol/vol) glycerol. In addition, 31 clarithromycin resistant and 27 sensitive strains which had been previously determined by minimum inhibitory concentration (MIC), were recovered from frozen stocks and used.

**GASTRIC JUICE SAMPLES**

Gastric juice samples were aspirated with disposable nasogastric tubes from 39 patients to compare the results of urease A (URA) PCR and 23S rRNA PCR. More samples from 28 pretreatment and 85 post-treatment patients were used for clinical application.

**PREPARATION OF DNA**

The culture medium was centrifuged for five minutes at 10,000 g, and genomic DNA from *H. pylori* isolates was extracted from the pellets using SepaGene (Sanko Junyaku, Japan). From the gastric juice samples, to avoid possible interference from substances in the gastric juice, *H. pylori* was first captured on rabbit anti- *H. pylori* antibody (Dako A/S, Denmark) immobilised on polystyrene beads. After elution from the beads, DNA was extracted using the SepaGene. DNA was stored at −20°C until use as PCR templates.

**SEQUENCE ANALYSIS OF 23S rRNA GENE**

To examine the nucleotide conservation in the region flanking 23S rRNA position 2143 and 2144, we amplified a segment of approximately 330 bp in seven *H. pylori* strains by using PCR primers 23SF2 (5'-GTGGGAATTCCTTGTGCATGG-3', corresponding to *H. pylori* 23S rRNA position 2015–2034) and 23SR (5'-GACCCTCCGTCGAAGAC-3', position 2343–2326). The PCR products were cloned into pCRII using the original TA cloning kit (Invitrogen, San Diego, California). The nucleotide sequence of the insert was determined by the dideoxy chain termination procedure.

**SPECIFIC PRIMERS FOR *H. PYLORI* AND AMPLIFICATION**

After analysing the sequence conservation among the seven clinically isolated *H. pylori* strains and the sequence specificity for *H. pylori* compared with other bacteria reported in GenBank, we chose one sense primer, CRF-4 (5'-AGTGGAGGTGAAAATTCC-3', corresponding to *H. pylori* 23SrRNA position 2105–2123), and two antisense primers, CRR-1 (5'-TGAGCCACCACAGCCCTAC-3', position 2239–2221), and CRR-3 (5'-ATGCTTTCCTGTTGGAATTC-3', position 2189–2172). A novel seminested PCR assay was thus designed with CRF-4/CRR-1 as the first and CRF-4/CRR-3 as internal PCR primers (23SrRNA PCR assay). A PCR cycle consisted of denaturation at 94°C for 30 seconds, annealing at 50°C for 30 seconds, and extension at 72°C for one minute: 30 cycles were performed for the first and 20 cycles for the second PCR amplification.

**DETECTION OF URE A GENE FROM GASTRIC JUICE SAMPLES**

DNA from gastric juice samples was also analysed using primers set in *ureA* gene described previously (URA PCR) and the results were compared with those of the 23S rRNA PCR assay.

**SPECIFICITY OF PRIMERS**

Specificity for *H. pylori* of the novel PCR primers, CRF-4/CRR-1 and CRF-4/CRR-3, was evaluated by testing cross reaction with DNA samples extracted from 12 bacterial species other than *H. pylori*. These bacterial species were *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Streptococcus pyogenes*, *Streptococcus mitis*, *Haemophilus parainfluenzae*, *Campylobacter jejuni*, *Aspergillus flavus*, *Proteus mirabilis*, *Klebsiella pneumoniae*, and *Brachymella catarrhalis*.

---

**Table 1** Treatment regimens

<table>
<thead>
<tr>
<th>Regimen</th>
<th>No of patients</th>
<th>Week</th>
<th>Lansoprazole (mg)</th>
<th>Amoxycillin (mg)</th>
<th>Clarithromycin (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LA</td>
<td>39</td>
<td>1</td>
<td>60</td>
<td>2000</td>
<td>–</td>
</tr>
<tr>
<td>LAC</td>
<td>39</td>
<td>1</td>
<td>60</td>
<td>2000</td>
<td>400</td>
</tr>
</tbody>
</table>

LA, lansoprazole + amoxycillin; LAC, lansoprazole + amoxycillin + clarithromycin.

The gastric juice samples, to avoid possible interference from substances in the gastric juice, *H. pylori* was first captured on rabbit anti-*H. pylori* antibody (Dako A/S, Denmark) immobilised on polystyrene beads. After elution from the beads, DNA was extracted using the SepaGene. DNA was stored at −20°C until use as PCR templates.

**SEQUENCE ANALYSIS OF 23S rRNA GENE**

To examine the nucleotide conservation in the region flanking 23S rRNA position 2143 and 2144, we amplified a segment of approximately 330 bp in seven *H. pylori* strains by using PCR primers 23SF2 (5'-GTGGGAATTCCTTGTGCATGG-3', corresponding to *H. pylori* 23S rRNA position 2015–2034) and 23SR (5'-GACCCTCCGTCGAAGAC-3', position 2343–2326). The PCR products were cloned into pCRII using the original TA cloning kit (Invitrogen, San Diego, California). The nucleotide sequence of the insert was determined by the dideoxy chain termination procedure.

**SPECIFIC PRIMERS FOR *H. PYLORI* AND AMPLIFICATION**

After analysing the sequence conservation among the seven clinically isolated *H. pylori* strains and the sequence specificity for *H. pylori* compared with other bacteria reported in GenBank, we chose one sense primer, CRF-4 (5'-AGTGGAGGTGAAAATTCC-3', corresponding to *H. pylori* 23SrRNA position 2105–2123), and two antisense primers, CRR-1 (5'-TGAGCCACCACAGCCCTAC-3', position 2239–2221), and CRR-3 (5'-ATGCTTTCCTGTTGGAATTC-3', position 2189–2172). A novel seminested PCR assay was thus designed with CRF-4/CRR-1 as the first and CRF-4/CRR-3 as internal PCR primers (23SrRNA PCR assay). A PCR cycle consisted of denaturation at 94°C for 30 seconds, annealing at 50°C for 30 seconds, and extension at 72°C for one minute: 30 cycles were performed for the first and 20 cycles for the second PCR amplification.

**DETECTION OF URE A GENE FROM GASTRIC JUICE SAMPLES**

DNA from gastric juice samples was also analysed using primers set in *ureA* gene described previously (URA PCR) and the results were compared with those of the 23S rRNA PCR assay.

**SPECIFICITY OF PRIMERS**

Specificity for *H. pylori* of the novel PCR primers, CRF-4/CRR-1 and CRF-4/CRR-3, was evaluated by testing cross reaction with DNA samples extracted from 12 bacterial species other than *H. pylori*. These bacterial species were *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Streptococcus pyogenes*, *Streptococcus mitis*, *Haemophilus parainfluenzae*, *Campylobacter jejuni*, *Aspergillus flavus*, *Proteus mirabilis*, *Klebsiella pneumoniae*, and *Brachymella catarrhalis*. This page is from a scientific journal article about the identification and culture of *H. pylori* and the analysis of gastric juice samples to detect *H. pylori* using PCR and sequencing techniques. The table lists treatment regimens for patients with *H. pylori* infection, and the sequence analysis and primers used for PCR amplification are described in detail.
PCR assay for detection of clarithromycin resistance

DETECTION OF 23S rRNA MUTATION ASSOCIATED WITH CLARITHROMYCIN RESISTANCE

To detect the A to G mutations at 23S rRNA gene positions 2143 and 2144, PCR products were digested with 5 U of MboII and BsaI at 37°C and 55°C respectively for two hours. PCR products containing the 2143 A to G mutation showed two smaller products after digestion with MboII, those containing the 2144 A to G mutation showed two smaller products after digestion with BsaI, and those containing no mutation revealed undigested amplicon.

DETERMINATION OF MIC TO CLARITHROMYCIN

The susceptibility of *H. pylori* isolates to clarithromycin was evaluated by the agar dilution method. Twenty seven strains without mutation and six strains with mutation were tested and the MIC was determined. The MIC was also determined in 31 strains from frozen stocks.

CLINICAL APPLICATION

Clinical applicability of the 23S rRNA PCR was evaluated in a total of 85 patients who received anti-*H. pylori* treatment. *H. pylori* infection was confirmed before treatment by culture, microscopy, rapid urease test, and URA PCR assay. The 23S rRNA-PCR detected the gene, with or without mutations, in all subjects before treatment. Seventy eight patients were treated; table 1 summarises the regimens. The outcome of antimicrobial therapy was assessed more than eight weeks after the completion of treatment. Gastric juice samples were aspirated with endoscopes or nasogastric strings, and the mutations at positions 2143 and 2144 of the *H. pylori* 23S rRNA gene were evaluated as described earlier.

STATISTICAL ANALYSIS

Fisher’s exact probability test was used. A value of p<0.05 was considered statistically significant.

<table>
<thead>
<tr>
<th>23S rRNA</th>
<th>URA PCR</th>
<th>Positive</th>
<th>Negative</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>29</td>
<td>2</td>
<td>31</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>0</td>
<td>8</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>29</td>
<td>10</td>
<td>39</td>
<td></td>
</tr>
</tbody>
</table>

Table 2 Comparison between the 23S rRNA PCR and URA PCR assays using gastric juice samples

Results

SEQUENCE ANALYSIS OF 23S rRNA GENE

Sequence analysis between 2042 to 2281 of the *H. pylori* 23S rRNA gene in seven clinical isolates revealed that a few positions had frequent nucleotide mutations while others were well conserved. Nucleotides were different from the standard at two positions in all clinical isolates. One strain (TN-5) had the resistance associated 2144 A to G mutation (fig 1).

PCR AMPLIFICATION

The primers used for the 23S rRNA PCR assay, CRF-4, CRR-1, and CRR-3, were designed to target the regions conserved in *H. pylori* strains but not shared by other bacteria. Using 10 ng of DNA extracted from culture, all DNA samples from 57 *H. pylori* isolates revealed positive amplification by the first step PCR. The results of the 23S rRNA PCR on gastric juice samples agreed with those of the URA PCR assay in 37/39 samples. Importantly, eight samples negative by the URA PCR assay were negative also by the 23S rRNA PCR assay. Thus, there were no apparent false positives (table 2). The specificity of the 23S rRNA PCR assay was also confirmed by the absence of cross reaction with DNA samples obtained from 12 bacterial species other than *H. pylori*.

DETECTION OF MUTATIONS

The 23S rRNA PCR products were incubated with two restriction enzymes, MboII and BsaI. Eighty five pretreatment patients were investigated, and overall, 8/85 (9%) had a point mutation associated with clarithromycin resistance. Only one sample was digested with MboII, indicating the 2143 A to G mutation. Seven samples were digested with BsaI, indicating the 2144 A to G mutation. Figure 2 shows typical examples. Six of the eight strains were shown to be clarithromycin resistant by the agar dilution method as expected. The remaining two were not tested because culture was not available. Twenty nine of 31 strains which were recovered from frozen stocks and previously determined as clarithromycin resistant by MIC had the 2144 mutation and only one strain had the 2143 mutation. The remaining strain had no mutation at either 2143 or 2144. Twenty seven strains susceptible to clarithromycin by the agar dilution method did not have a mutation at either 2143 or 2144 (fig 3).

CLINICAL APPLICATION

The mutations in the *H. pylori* 23S rRNA gene were revealed in 8/85 (9%) samples obtained before treatment. Thirty nine patients, including three infected with mutant strains, received regimens without clarithromycin. Eradication was achieved in 1/3 (33%) patients with mutant infection and 12/36 (33%) patients with wild type infection (NS). After treatment, sustained mutant infection was confirmed in two patients who had mutant strains before treatment, but all 24 patients with wild type infection before treatment still harboured wild types. Thirty nine other patients were treated...

![Image](http://gut.bmj.com/)

Figure 2 Detection of A to G mutation. PCR products from four strains were digested with MboII (lanes 1–4) and with BsaI (lanes 1–4). Strain 2 had the A to G mutation at 2143 (lane 2), strain 1 had the A to G mutation at 2144 (lane 1), and strains 3 and 4 had no mutations at either 2143 or 2144.
12 hours, assessing *H pylori* infection and clarithromycin resistance simultaneously. The high sensitivity of the assay was due to the good conservation of the sequences targeted by its primers among *H pylori* strains. The seminining of PCR amplification was also essential for its high sensitivity. The novel 23S rRNA PCR and the URA PCR agreed in 37/39 gastric juice samples. Importantly, the 23S rRNA PCR resulted in no false positive results.

Clarithromycin resistance of *H pylori* was reported to be due to the point mutation of 23S rRNA by Versalovic et al.19 We confirmed that this finding also applies to *H pylori* isolates in Japan. We tested 37 clarithromycin resistant strains and 27 susceptible strains as determined by MIC; 36/37 resistant strains and 0/27 susceptible strains had the mutation. These results show that most strains resistant to clarithromycin have the mutations in the 23S rRNA gene. However, one clarithromycin resistant strain has no mutation at positions 2143 or 2144 by both our assay and sequence analysis (data not shown) and the mechanism of resistance remains to be investigated.

In the present study, 36/38 (95%) strains with the mutation associated with clarithromycin resistance revealed the A to G mutation at position 2143, and only 2/38 (5%) had that at position 2144. Recently, Stone et al showed that a higher level of resistance was associated with the A to G mutation at 2143.21 Seven strains examined in this study had MIC values greater than 50 µg/ml, and the MIC of other resistant strains ranged from 3 to 32 µg/ml. The relatively low level of MIC in the isolates may be related to the high prevalence of the A to G mutation at position 2144 in Japan. Although the overall prevalence of clarithromycin resistant strains is similar in Japan and Western countries, the difference in the mutation position may have affected the eradication rates of clarithromycin based treatments. To confirm these observations, further clinical trials using this assay will be necessary.

Recently it was reported that the A to C mutation at position 2143 was also associated with clarithromycin resistance.21 The authors also reported that 7% of clarithromycin resistant strains had this mutation. Our assay is not able to detect the A to C mutation. However, in 37 clarithromycin resistant isolates determined by MIC, we found no strain with the A to C mutation, and the sensitivity of the assay seems to be practically sufficient, at least in Japan. The clinical applicability of this assay in other countries needs to be investigated. To establish a more sensitive detection system, we are developing an assay to detect all mutations associated with clarithromycin resistance.

Anti-*H pylori* treatment with clarithromycin, together with amoxycillin and a proton pump inhibitor, is one of the current standard protocols. However, several studies have indicated that *H pylori* may become clarithromycin resistant after an unsuccessful clarithromycin based treatment.22 23 Indeed, the present study confirmed genotypically the appearance of clarithromycin resistance. It has also been shown that the eradication rates achieved by

### Table 3 Result of clinical application

<table>
<thead>
<tr>
<th>Regimen</th>
<th>No of patients</th>
<th>Before</th>
<th>After</th>
<th>Acquired mutation</th>
<th>Treatment success</th>
</tr>
</thead>
<tbody>
<tr>
<td>LA</td>
<td>39</td>
<td>3/39</td>
<td>2/6</td>
<td>0</td>
<td>12 (33%)</td>
</tr>
<tr>
<td>LAC</td>
<td>39</td>
<td>5/39</td>
<td>5/8</td>
<td>2</td>
<td>31 (79%)</td>
</tr>
</tbody>
</table>

LA, lansoprazole + amoxycillin; LAC, lansoprazole + amoxycillin + clarithromycin.

with regimens containing clarithromycin; five had mutant strains before treatment. Eradication was achieved in 2/5 (40%) patients with mutant infection and in 29/34 (85%) patients with wild type infection (p<0.05). Post-treatment 23S rRNA PCR assay revealed the clarithromycin resistance mutations in 3/3 (100%) patients with mutant infection before treatment and 2/5 (40%) patients with wild type infection before treatment. Thus, the proportion of mutant infection increased from 5/39 (13%) to 5/8 (63%) among this group (table 3).

### Discussion

We have developed an assay that can detect *H pylori* infection with high sensitivity and simultaneously evaluate clarithromycin resistance. As 23S rRNA genes are fairly conserved among various bacterial species, PCR amplification of DNA directly extracted from gastric biopsy or gastric juice samples may be affected by the 23S rRNA gene of other bacteria if non-specific primers are used. Thus, the detection of the mutations in the 23S rRNA gene associated with clarithromycin resistance with consensus primers requires culture before extraction of DNA and PCR-RFLP; this takes about 10 days. In contrast, our novel assay does not require culture and can be completed in only

![figure 3](http://gut.bmj.com/)

Relation between the A to G mutation at 2143/2144 and MIC. All strains with the mutation at 2143/2144 were resistant to clarithromycin by MIC. One strain was resistant by MIC but had no mutation. Those without the mutations were susceptible to clarithromycin by MIC.

with regimens containing clarithromycin; five had mutant strains before treatment. Eradication was achieved in 2/5 (40%) patients with mutant infection and in 29/34 (85%) patients with wild type infection (p<0.05). Post-treatment 23S rRNA PCR assay revealed the clarithromycin resistance mutations in 3/3 (100%) patients with mutant infection before treatment and 2/5 (40%) patients with wild type infection before treatment. Thus, the proportion of mutant infection increased from 5/39 (13%) to 5/8 (63%) among this group (table 3).

### Discussion

We have developed an assay that can detect *H pylori* infection with high sensitivity and simultaneously evaluate clarithromycin resistance. As 23S rRNA genes are fairly conserved among various bacterial species, PCR amplification of DNA directly extracted from gastric biopsy or gastric juice samples may be affected by the 23S rRNA gene of other bacteria if non-specific primers are used. Thus, the detection of the mutations in the 23S rRNA gene associated with clarithromycin resistance with consensus primers requires culture before extraction of DNA and PCR-RFLP; this takes about 10 days. In contrast, our novel assay does not require culture and can be completed in only

![figure 3](http://gut.bmj.com/)

Relation between the A to G mutation at 2143/2144 and MIC. All strains with the mutation at 2143/2144 were resistant to clarithromycin by MIC. One strain was resistant by MIC but had no mutation. Those without the mutations were susceptible to clarithromycin by MIC.

with regimens containing clarithromycin; five had mutant strains before treatment. Eradication was achieved in 2/5 (40%) patients with mutant infection and in 29/34 (85%) patients with wild type infection (p<0.05). Post-treatment 23S rRNA PCR assay revealed the clarithromycin resistance mutations in 3/3 (100%) patients with mutant infection before treatment and 2/5 (40%) patients with wild type infection before treatment. Thus, the proportion of mutant infection increased from 5/39 (13%) to 5/8 (63%) among this group (table 3).

### Discussion

We have developed an assay that can detect *H pylori* infection with high sensitivity and simultaneously evaluate clarithromycin resistance. As 23S rRNA genes are fairly conserved among various bacterial species, PCR amplification of DNA directly extracted from gastric biopsy or gastric juice samples may be affected by the 23S rRNA gene of other bacteria if non-specific primers are used. Thus, the detection of the mutations in the 23S rRNA gene associated with clarithromycin resistance with consensus primers requires culture before extraction of DNA and PCR-RFLP; this takes about 10 days. In contrast, our novel assay does not require culture and can be completed in only

![figure 3](http://gut.bmj.com/)

Relation between the A to G mutation at 2143/2144 and MIC. All strains with the mutation at 2143/2144 were resistant to clarithromycin by MIC. One strain was resistant by MIC but had no mutation. Those without the mutations were susceptible to clarithromycin by MIC.

with regimens containing clarithromycin; five had mutant strains before treatment. Eradication was achieved in 2/5 (40%) patients with mutant infection and in 29/34 (85%) patients with wild type infection (p<0.05). Post-treatment 23S rRNA PCR assay revealed the clarithromycin resistance mutations in 3/3 (100%) patients with mutant infection before treatment and 2/5 (40%) patients with wild type infection before treatment. Thus, the proportion of mutant infection increased from 5/39 (13%) to 5/8 (63%) among this group (table 3).

### Discussion

We have developed an assay that can detect *H pylori* infection with high sensitivity and simultaneously evaluate clarithromycin resistance. As 23S rRNA genes are fairly conserved among various bacterial species, PCR amplification of DNA directly extracted from gastric biopsy or gastric juice samples may be affected by the 23S rRNA gene of other bacteria if non-specific primers are used. Thus, the detection of the mutations in the 23S rRNA gene associated with clarithromycin resistance with consensus primers requires culture before extraction of DNA and PCR-RFLP; this takes about 10 days. In contrast, our novel assay does not require culture and can be completed in only

![figure 3](http://gut.bmj.com/)

Relation between the A to G mutation at 2143/2144 and MIC. All strains with the mutation at 2143/2144 were resistant to clarithromycin by MIC. One strain was resistant by MIC but had no mutation. Those without the mutations were susceptible to clarithromycin by MIC.
clarithromycin based regimens significantly differed between mutant and wild type infections. Thus, regimens not containing clarithromycin may be preferable in cases with mutant *H pylori* infections. The prevalence of mutant infection is likely to be high among cases where the initial clarithromycin based treatment failed to achieve eradication, and the assessment of mutation will be more important in those cases. The 23S rRNA PCR, which does not require culture and can use gastric juice samples, may be useful under these circumstances.

In conclusion, we have established a highly sensitive seminested PCR assay for both the detection of *H pylori* infection and the evaluation of the 23S rRNA mutation associated with clarithromycin resistance. By using gastric juice samples, the assay is rapid (overnight) and less invasive (no need to perform biopsy), and patients can be treated with adequate antibiotics, based on knowledge of the resistance of the infecting organism.

Presented in part at the American Gastroenterological Association meeting in Washington, DC, 10–16 May 1997.